Markets:

Overview

News

Currencies

International

Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.120 -0.110 (-2.60%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 20, 2024

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and...

Via Benzinga

Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher ↗

March 20, 2024

U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P...

Via Benzinga

Topics Economy Stocks

A Stock Split Catalyst Looms for Chipotle (CMG) Stock on June 6 ↗

March 20, 2024

Chipotle stock is rising on Wednesday as investors in CMG shares react to the company seeking approval for a 50-for-one split.

Via InvestorPlace

A Preview Of Aquestive Therapeutics's Earnings ↗

March 04, 2024

Via Benzinga

Where Aquestive Therapeutics Stands With Analysts ↗

November 08, 2023

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Preview: Aquestive Therapeutics's Earnings ↗

November 03, 2023

Via Benzinga

INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost ↗

March 20, 2024

Intel stock is rising on Wednesday as investors in INTC shares react to the semiconductor company securing $8.5 billion in funding.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 20, 2024

Via Benzinga

Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today? ↗

March 20, 2024

Aquestive Therapeutics stock is falling on Wednesday after the company price a public offering for AQST shares this morning.

Via InvestorPlace

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket ↗

March 20, 2024

Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 20, 2024

Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!

Via InvestorPlace

Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

March 20, 2024

U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday.

Via Benzinga

Topics Stocks

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

March 19, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 19, 2024

Via Benzinga

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

March 19, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗

March 15, 2024

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.

Via Benzinga

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 15, 2024

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.

Via Benzinga

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

March 14, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 08, 2024

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.

Via Benzinga

AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗

March 05, 2024

AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 05, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

February 21, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

February 15, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

January 30, 2024

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

December 05, 2023

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

November 10, 2023

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 06, 2023

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

November 02, 2023

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.